证券代码：002349 证券简称：精华制药 公告编号：2024-016 精华制药集团股份有限公司 第六届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"、"本公司"、"精华制药"） 第六届董事会第一次会议于2024年5月17日（星期五）以现场和通讯相结合方式 在公司会议室召开。会议应出席董事7名，出席董事7名，公司监事、高级管理人 员列席了会议，会议的召开符合《中华人民共和国公司法》及《公司章程》的有 关规定，会议的召集、召开合法有效。与会董事一致推选尹红宇先生主持会议。 1、审议通过了《关于换届选举董事长的议案》。 会议选举尹红宇先生为公司第六届董事会董事长，任期三年。 表决结果：7票赞成；0票弃权；0票反对。 2、审议通过了《关于换届选举副董事长的议案》。 会议选举吴玉祥先生为公司第六届董事会副董事长，任期三年。 表决结果：7票赞成；0票弃权；0票反对。 3、审议通过了《关于选举第六届董事会各专门委员会的议案》。 王煦先生、尹红宇先生、张晓梅女士为董事会提名委员会委员，王煦先生 ...

北京市盈科（南通）律师事务所 关于精华制药集团股份有限公司 2023年年度股东大会法律意见书 致：精华制药集团股份有限公司 受贵公司的委托，北京市盈科（南通）律师事务所（以下简称 "本所"）根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东大会规则》(以下简称"《股东大会规则》")等法 律、法规、规章及《精华制药集团股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，就贵公司2023年年度股东大会（以 下简称"本次股东大会"）有关事宜，出具本法律意见。本法律意 见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员 的资格、召集人资格、会议表决程序是否符合中国相关法律、法规 及《公司章程》的规定以及表决结果是否合法有效发表意见，并不 对本次股东大会所审议的议案内容以及该等议案所表述的相关事 实或数据的真实性、准确性或合法性发表意见。 本法律意见书仅供见证本次股东大会相关事项合法性之目的 而使用，未经本所书面同意，任何人不得将其用作其他任何目的。 为出具本法律意见之目的，本所委派汪秋语律师、刘姗姗律师 列席了贵公司本次股东大会会议，并根据现行法律、法规的有关规 定及要求，按照律 ...

证券代码：002349 证券简称：精华制药 公告编号：2024-015 2023年年度股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 特别提示： 本 次 会 议 的 通 知 已 于 2024 年 4 月 19 日 在 《 巨 潮 资 讯 网 》 （http://www.cninfo.com.cn）、《证券时报》上发出，本次会议召开期间无增加、 否决或变更提案的情况，未出现变更前次股东大会决议情况。 一、会议召开和出席情况 精华制药集团股份有限公司（以下简称"公司"）2023年年度股东大会采取现 场投票与网络投票相结合方式进行，现场会议于2024年5月17日下午14:00在公司会 议室召开，会议由公司董事会召集，由董事长尹红宇先生主持。公司董事、监事、 董事候选人、监事候选人、高级管理人员出席了会议。通过深圳证券交易所交易系 统进行网络投票的时间为2024年5月17日上午9:15-9:25，9:30-11:30 和下午13:00～ 15:00；通过深圳证券交易所互联网投票系统投票的时间为2024年5月17日上午9:15 至下午15: ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥367,129,069.92, a decrease of 11.82% compared to ¥416,357,917.91 in the same period last year[5] - Net profit attributable to shareholders was ¥71,080,090.21, down 18.92% from ¥87,671,328.30 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0873, reflecting an 18.94% decline from ¥0.1077 in the same period last year[5] - Total operating revenue for the current period is ¥367,129,069.92, a decrease of 11.8% from ¥416,357,917.91 in the previous period[20] - Net profit for the current period is ¥81,983,042.72, a decline of 17.1% compared to ¥99,041,270.14 in the previous period[22] - The company reported a total profit of ¥95,867,429.67, down 17.5% from ¥116,172,239.12 in the previous period[22] Cash Flow and Investments - The net cash flow from operating activities increased significantly to ¥30,919,958.81, compared to a negative cash flow of ¥5,318,150.98 in the previous year, representing a 681.40% improvement[5] - Cash received from operating activities increased by 61.98% to CNY 13,437,527.22, primarily due to increased cash from subsidiary Dongli Chemical[9] - Cash recovered from investments dropped by 80.73% to CNY 10,000,000.00, attributed to higher redemptions of financial products in the previous year[9] - Investment income cash received fell by 81.57% to CNY 47,798.48, mainly due to lower returns from redeemed financial products compared to the previous year[9] - Investment activities resulted in a net cash outflow of ¥62,645,591.74, compared to a smaller outflow of ¥5,548,102.56 in the previous period[24] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,213,710,291.74, a slight increase of 0.90% from ¥3,185,011,365.95 at the end of the previous year[5] - Current assets totaled CNY 2,039,492,379.66, up from CNY 1,985,809,222.46 at the start of the quarter, indicating a growth of approximately 2.7%[17] - Total liabilities decreased to CNY 326,254,202.53 from CNY 380,746,462.33, a reduction of approximately 14.3%[18] - The equity attributable to shareholders rose to ¥2,516,644,496.19, marking a 2.95% increase from ¥2,444,593,197.18 at the end of the last year[5] - The equity attributable to the owners of the parent company increased to CNY 2,516,644,496.19 from CNY 2,444,593,197.18, reflecting a growth of about 2.9%[19] Income and Expenses - Total operating costs decreased to ¥278,288,740.26, down 6.8% from ¥298,578,026.85[20] - Financial expenses decreased significantly, with a reported amount of -¥10,177,062.05, indicating a 2923.92% change due to increased deposit income and reduced bank loan interest[8] - Other income increased by 309.45% to ¥4,180,842.03, primarily due to higher government subsidies received[8] - Research and development expenses increased to ¥17,109,278.74, up 29.5% from ¥13,215,026.76[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 129,620[11] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds a 34.39% stake with 279,994,660 shares[11] - The company has no preferred shareholders with restored voting rights at the end of the reporting period[11] - The total number of shareholders with priority shares was not applicable for this report period[16] Other Information - The company received government subsidies amounting to ¥2,943,257.89 during the quarter, contributing to its financial performance[6] - The company reported a significant increase in fair value gains of 216.42%, amounting to ¥2,866,682.19, attributed to favorable returns on financial products[8] - Tax refunds received decreased by 81.78% to CNY 160,334.05 due to increased input tax refunds and export tax rebates in the previous year[9] - Cash paid for the purchase of fixed assets increased by 83.69% to CNY 14,172,110.99, reflecting higher capital expenditures by subsidiary Senxuan Pharmaceutical[9] - Cash paid for other investment activities surged by 1168.44% to CNY 568,291.67, indicating increased cash outflows from the parent company[9] - The impact of exchange rate fluctuations on cash and cash equivalents was a negative CNY 1,838,051.23, a decrease of 147.65% due to changes in the USD exchange rate[9] - The company has not disclosed any new product developments or market expansion strategies in this quarter[16]

精华制药集团股份有限公司 2023 年度财务报表审计报告 天衡审字(2024) 00714 号 天衡会计师事务所(特殊普通合伙) 化码用于证明该审计报告是否由具有执业许可的会计师事务 主册会计师行业统一监管平台（http://gcc.mof.vov.cn) 您可使用手机"扫一扫"或进入"注册 审计报告 天衡审字(2024)00714号 精华制药集团股份有限公司全体股东: 一、审计意见 我们审计了精华制药集团股份有限公司(以下简称精华制药公司)财务报表,包括 2023年12月31日的合并及母公司资产负债表,2023年度的合并及母公司利润表、合并及母 公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映 了精华制药公司2023年12月31日的合并及母公司财务状况以及2023年度的合并及母公司经 营成果和现金流量。 (二)存货的可变现净值 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师 对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计 师职业道德守 ...

关于精华制药集团股份有限公司 2023 年度非经营性资金占用及其他关联 资金往来情况的专项说明 天衡专字(2024)00302 号 e and 天衡会计师事务所(特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业综一些答亚会 关于精华制药集团股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况的专项说明 天衡专字(2024)00302 号 精华制药集团股份有限公司全体股东: 本专项说明仅供精华制药公司向中国证券监督管理委员会和证券交易所报送精华制药 公司年度报告使用,未经本事务所书面同意,不得用于其他用途。 附件:精华制药集团股份有限公司 2023年度非经营性资金占用及其他关联资金往来情况 汇总表 干角 中国注册会计师:邱平 中国注册会计师:谢谦 我们接受委托,审计了精华制药集团股份有限公司(以下简称"精华制药公司")财务 报表,包括 2023年12月31日的合并及母公司资产负债表,2023年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注，并出 具了天衡审字(2023)00361 号审计报告。 根据中国证券监督管理委员会《上市公司监管指 ...

证券代码：002349 证券简称：精华制药 公告编号：2024-010 精华制药集团股份有限公司 关于2023年度计提减值准备的公告 公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、误 导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召开 第五届董事会第十八次会议、第五届监事会第十三次会议，审议通过了《关于 2023 年度计提减值准备的议案》，现根据《深圳证券交易所上市公司自律监管指 南第 1 号—业务办理》等规定，将具体情况公告如下： 一、本次计提资产减值准备情况概述 1、整体情况 根据《企业会计准则》、《深圳证券交易所上市公司自律监管指南第 1 号—业 务办理》等相关规定的要求，为更加真实、准确地反映公司截至 2023 年 12 月 31 日的资产状况和财务状况，公司及下属子公司于 2023 年末对存货、应收款项、 固定资产等各类资产进行了全面清查。在清查的基础上，对各类存货的可变现净 值、应收款项回收可能性、固定资产的可变现性金额、商誉是否减值等进行了减 值测试，判断存在可能发生减值的迹象，对可能发生资产减值损失的资产 ...

Financial Performance - The company's operating revenue for 2023 was approximately CNY 1.51 billion, a decrease of 3.90% compared to CNY 1.57 billion in 2022[23]. - Net profit attributable to shareholders increased by 16.71% to CNY 247.70 million in 2023, up from CNY 212.23 million in 2022[23]. - The net profit after deducting non-recurring gains and losses rose by 35.00% to CNY 237.26 million in 2023, compared to CNY 175.76 million in 2022[23]. - The net cash flow from operating activities decreased by 18.72% to CNY 291.31 million in 2023, down from CNY 358.39 million in 2022[23]. - Basic earnings per share increased by 16.69% to CNY 0.3042 in 2023, compared to CNY 0.2607 in 2022[23]. - Total assets at the end of 2023 were CNY 3.19 billion, reflecting a 4.70% increase from CNY 3.04 billion at the end of 2022[23]. - The net assets attributable to shareholders increased by 1.82% to CNY 2.44 billion at the end of 2023, compared to CNY 2.40 billion at the end of 2022[23]. - In 2023, the company achieved consolidated revenue of CNY 1.511 billion, a year-on-year increase of approximately 10% after excluding the sale of Jin Silin Pharmaceutical[69]. - The net profit attributable to the parent company reached CNY 248 million, representing a year-on-year growth of about 16.71%[69]. - The cash flow from operating activities was CNY 291 million, with tax revenue increasing by 30% to CNY 173 million[69]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 0.92 RMB per 10 shares (including tax) based on a total of 814,180,908 shares[4]. - The company distributed a cash dividend of 0.80 yuan per 10 shares, totaling 65,134,472.64 yuan for the 2022 fiscal year[160]. - The cash dividend policy was executed in accordance with the company's articles of association and shareholder resolutions, with a total cash dividend amounting to 74,904,643.54 yuan for the current period[161]. - The cash dividend distribution accounted for 100% of the profit distribution total, aligning with the company's mature development stage[161]. Market and Industry Trends - The pharmaceutical industry in China saw a decline in added value of 5.2% in 2023, with total revenue dropping by 4% to CNY 2.96 trillion[34]. - The demand for health management and chronic disease management products is expected to grow significantly due to the aging population, with the elderly health industry projected to expand from 2021 to 2035[35]. - The long-term prescription policy for chronic diseases has been implemented across various provinces, enhancing the accessibility of medications for stable chronic disease patients, which benefits the company's product sales[38]. - The Chinese government has introduced multiple supportive policies for traditional Chinese medicine (TCM), aiming for high-quality development in the sector, which aligns with the company's strategic focus[39]. - The average price reduction for 15 types of traditional Chinese medicine in the centralized procurement process was 49.36%, indicating a significant shift in pricing dynamics within the industry[44]. Product Development and R&D - The company invested CNY 64.62 million in R&D in 2023, resulting in 9 authorized invention patents and 29 utility model patents[71][72]. - The company is conducting clinical trials for new products, including the Wang's Baoshizhuan treatment for infant functional dyspepsia, which aims to enhance product competitiveness[86]. - The company is committed to innovation, with ongoing projects including the consistency evaluation of Phenobarbital tablets and the development of new products in collaboration with partners[113]. - The company is investing in infrastructure projects, including a 40-ton annual production capacity for Ritonavir and a 60-ton capacity for Buflomedil raw materials[115]. Compliance and Governance - The company has established a complete independent financial management system, ensuring no shared bank accounts with controlling shareholders[130]. - The company has improved its corporate governance structure in compliance with relevant laws and regulations[127]. - The company is committed to maintaining transparency and accountability in its financial reporting practices[150]. - The company has a fully independent employee management system, ensuring no personnel overlap with shareholders[129]. - The company has implemented a performance-based assessment for remuneration since March 2022[144]. Environmental Compliance - The company has obtained environmental permits for its projects, with the latest permit valid until March 12, 2028[176]. - The company’s waste gas and wastewater emissions comply with relevant environmental standards, including the Jiangsu Province standards for the pharmaceutical industry[171]. - The company has completed environmental impact assessments for multiple projects, with ongoing assessments for new phases[176]. - The company has a valid wastewater discharge permit effective from September 28, 2022, to September 27, 2027[176]. - The company has successfully passed all required environmental evaluations for its production facilities[176]. Challenges and Risks - The company faces risks related to regulatory changes, including the implementation of DRG/DIP payment reforms by the end of 2024, which may impact its sales strategies[117]. - The company is exposed to raw material procurement risks due to the volatility in prices and supply shortages of traditional Chinese medicinal materials[119]. - The company anticipates potential declines in product sales prices due to government pricing adjustments and market competition[120]. - The company recognizes the risk of talent shortages as it expands its operations and business scope[123]. Future Outlook - Future outlook includes a projected revenue growth of 10% for 2024, driven by new product launches and market expansion strategies[136]. - The management emphasized the importance of sustainability in operations, aiming for a 30% reduction in carbon footprint by 2025[137]. - The company plans to enhance digital marketing efforts, targeting a 25% increase in online sales channels[138]. - A strategic partnership with a leading biotech firm is in the works, which is anticipated to accelerate product development timelines[139].

证券代码: 002349 证券简称: 精华制药 一、被提名人已经通过精华制药集团股份有限公司股份有限公司第5届董事会提名委员会或者独立董事专门会议资格审 精华制药集团股份有限公司 独立董事提名人声明与承诺 则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任公司董事的情形。 √ 是 □ 否 三、被提名人符合中国证监会《上市公司独立董事管理办法》和深圳证券交易所业务规则规定的独立董事任职资格和条 件。 提名人精华制药集团股份有限公司董事会现就提名王煦 精华制药集团股份有限公司 6届董事会独立董事候选人 发表公开声明。被提名人已书面同意出任精华制药集团股份有限公司 6届董事会独立董事候选人（参见该独立董事候 选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记 录等情况后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规 六、被提名人担任独立董 ...

经核查，截至本意见出具之日，公司在任独立董事王煦、冯巧根、马玲未在 公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任何职务， 与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断 的关系，不存在无法独立履行职责的情形，其独立性符合《上市公司独立董事管 理办法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第1号——主板上市公司规范运作》等相关要求。 精华制药集团股份有限公司董事会 2024年4月17日 精华制药集团股份有限公司董事会 关于独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等要求， 精华制药集团股份有限公司（以下简称"公司"）董事会结合公司在任独立董事王 煦、冯巧根、马玲的任职经历以及签署的相关自查文件，就其独立性情况进行评 估并出具如下专项意见： ...